培门冬酶治疗结外NK/T细胞淋巴瘤的疗效及安全性分析  

PEG- asparaginase: Therapeutic Efficacy and Safety in Patients with Extranodal NK /T- cell Lymphoma

作　　者：欧阳周[1] 易平勇[1] 孙中义[1] 黄利军[1] 贺军侨[1] 

机构地区：[1]中南大学湘雅医学院附属肿瘤医院淋巴瘤血液内科,湖南省长沙市410013

出　　处：《中国全科医学》2014年第18期2136-2138,共3页Chinese General Practice

摘　　要：目的：探讨培门冬酶治疗结外NK/T细胞淋巴瘤的疗效及安全性。方法选择2012年1月-2013年9月中南大学湘雅医学院附属肿瘤医院淋巴瘤血液内科收治的结外NK/T细胞淋巴瘤（鼻型）患者28例，按治疗药物的不同将患者分成左旋门冬酰胺酶组（13例）和培门冬酶组（15例）。左旋门冬酰胺酶组接受左旋门冬酰胺酶联合吉西他滨、奥沙利铂、地塞米松治疗，培门冬酶组接受培门冬酶联合吉西他滨、奥沙利铂、地塞米松治疗，同时两组均结合放疗。比较两组治疗有效率及不良反应发生率。结果28例患者的总有效率为89.3％（25/28）。左旋门冬酰胺酶组有效率为84.6％（11/13），培门冬酶组有效率为93.3％（14/15），差异无统计学意义（χ2＝0.553，P＝0.457）。左旋门冬酰胺酶组患者3~4度消化道反应、高血糖（空腹血糖＞7.0 mmol/L）、过敏反应的发生率均高于培门冬酶组（P＜0.05）。结论培门冬酶对结外NK/T细胞淋巴瘤的近期治疗效果较好，且较左旋门冬酰胺酶不良反应发生率低，安全性高，为临床治疗提供了有益参考。Objective To explore the therapeutic efficacy and adverse reactions of PEG-asparaginase in patients with extranodal NK/T-cell lymphoma. Methods Twenty-eight patients with extranodal NK/T-cell lymphoma from January 2012 to September 2013 in department of lymphoma and hematology,Affiliated Tumor Hospital of Xiangya Medical School,Central South University. Different drug treatment were divided into groups A（ given L-asparaginase combined with gemxibine,oxali-platine,dexamisone,n=13）,B（given PEG-asparaginase combined with gemxibine,oxaliplatine,dexamisone,n=15）. The 2 groups were also given radiotherapy. The effective rate,adverse reactions were compared between 2 groups. Results The total effective rate was 89. 3%（ 25/28 ）. The effective rate of group A was 84. 6%（ 11/13 ）, that of group B was 93. 3%（14/15）,the difference was not significant（χ2 =0. 553,P=0. 457）. The incidences of 3-4 degrees of gastrointestinal reac-tion,hyperglycemia（FPG〉7. 0 mmol/L）,anaphylactic reaction in group A were higher than those in group B（P〈;0. 05）. Conclusion PEG-asparaginase is of good therapeutic effects on extranodal NK/T-cell lymphoma,and its incidence of adverse reactions is lower and safety higher than those of L-asparaginase,which provides helpful basis for clinical treatment.

关 键 词：淋巴瘤 结外NKT细胞 左旋门冬酰胺酶 培门冬酶 治疗结果 不良反应 

分 类 号：R733.41[医药卫生—肿瘤]